Related references
Note: Only part of the references are listed.Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
Wei Chong et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2021)
Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
Qinghua Wang et al.
Aging-US (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma
Xueyong Zheng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
Fuyan Shi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Immune Modulatory Properties of Collagen in Cancer
Anne Mette Askehoj Romer et al.
FRONTIERS IN IMMUNOLOGY (2021)
COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells
Yi-Hui Wu et al.
ONCOGENE (2021)
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
Mingdong Lu et al.
NPJ PRECISION ONCOLOGY (2021)
COL11A1 Was Involved in Cell Proliferation, Apoptosis and Migration in Non-Small Cell Lung Cancer Cells
Hongbin Tu et al.
JOURNAL OF INVESTIGATIVE SURGERY (2021)
Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Qinghua Wang et al.
AGING-US (2020)
Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer
Wei Li et al.
ONCOTARGETS AND THERAPY (2020)
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
David A. Braun et al.
NATURE MEDICINE (2020)
High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
Qinghua Wang et al.
AGING-US (2020)
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein et al.
CLINICAL CANCER RESEARCH (2020)
Downregulation of Collagen COL4A6 Is Associated with Prostate Cancer Progression and Metastasis
Jian-Bin Ma et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2020)
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
Oliver Klein et al.
JAMA ONCOLOGY (2020)
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
Riyue Bao et al.
GENOME MEDICINE (2020)
COL4A family: potential prognostic biomarkers and therapeutic targets for gastric cancer
Xi Zeng et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
Lei Zhang et al.
JAMA NETWORK OPEN (2020)
Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
Hao Chen et al.
ONCOIMMUNOLOGY (2020)
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Bailiang Li et al.
CLINICAL CANCER RESEARCH (2019)
The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
Hao Chen et al.
ONCOIMMUNOLOGY (2019)
The role of collagen in cancer: from bench to bedside
Shuaishuai Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
Feng Wang et al.
JAMA ONCOLOGY (2019)
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
David A. Braun et al.
JAMA ONCOLOGY (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Qingzhu Jia et al.
JCI INSIGHT (2019)
A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma
X. C. Li et al.
ANNALS OF ONCOLOGY (2018)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
Xiangchun Li et al.
JAMA ONCOLOGY (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Jaegil Kim et al.
NATURE GENETICS (2016)
Oncotator: Cancer Variant Annotation Tool
Alex H. Ramos et al.
HUMAN MUTATION (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer
Y-H Wu et al.
ONCOGENE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Matthew D. Wilkerson et al.
BIOINFORMATICS (2010)
Share Paper
